An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials

BACKGROUND: With the emergence of molecularly targeted agents and immunotherapies, the landscape of phase I trials in oncology has been changed. Though these new therapeutic agents are very likely induce multiple low- or moderate-grade toxicities instead of DLT, most of the existing phase I trial de...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Rongji, Hu, Zongliang, Xu, Guoying, Pan, Haitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667395/
https://www.ncbi.nlm.nih.gov/pubmed/34895153
http://dx.doi.org/10.1186/s12874-021-01455-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667395/
https://www.ncbi.nlm.nih.gov/pubmed/34895153
http://dx.doi.org/10.1186/s12874-021-01455-y

Ejemplares similares